Hyperlipidemia

CDC: More People With High Cholesterol Taking Medications

CDC: More People With High Cholesterol Taking Medications

There has been a substantial increase in the percentage of patients with high cholesterol over age 60 years taking lipid-lowering medications from 2005 to 2016, but such increases have not been seen among younger patients with high cholesterol.

Revised Pooled Cohort Equations for CVD Risk Improve Accuracy of Estimates

Revised Pooled Cohort Equations for CVD Risk Improve Accuracy of Estimates

Investigators revised pooled cohort equations to improve clinical accuracy to predict risk for cardiovascular disease.

Cardiovascular Outcomes in Patients With ACS, Diabetes Using Alirocumab

Cardiovascular Outcomes in Patients With ACS, Diabetes Using Alirocumab

By

Investigators examine the effects of the PCSK9 inhibitor alirocumab in patients with recent acute coronary syndrome and diabetes.

Elevated Triglycerides, Diabetes May Be Predictors of Major Cardiovascular Events

Elevated Triglycerides, Diabetes May Be Predictors of Major Cardiovascular Events

By

Investigators examined cardiovascular outcomes in patients with elevated triglyceridemia and diabetes treated with statins.

LDL-C Reduction Examined With Different Evolocumab Dosing Regimens

LDL-C Reduction Examined With Different Evolocumab Dosing Regimens

By

For this study, researchers investigated the pharmacodynamics of evolocumab in two Phase 2 placebo-controlled studies (MENDEL and LAPLACE-TIMI 57) in order to determine which dosing regimens provided the most consistent LDL-C reduction.

Rheumatoid Arthritis Not as Likely to Increase CVD Risk as Diabetes

Rheumatoid Arthritis Not as Likely to Increase CVD Risk as Diabetes

Using both public and private health insurance claims data, investigators conducted a retrospective cohort study to assess cardiovascular risk in the setting of diabetes and rheumatoid arthritis.

Statins Beneficial for High-Risk Patients Despite Adverse Reactions

Statins Beneficial for High-Risk Patients Despite Adverse Reactions

By

From 25% to 50% of patients discontinue statins within 6 months to 1 year of starting, and the rate increases as high as 75% after 2 years.

FDA Approves Pitavastatin for Hyperlipidemia, Mixed Dyslipidemia

FDA Approves Pitavastatin for Hyperlipidemia, Mixed Dyslipidemia

By

Multiple clinical studies have examined the efficacy of pitavastatin.

Hydroxychloroquine May Lower Hyperlipidemia Risk in Early Rheumatoid Arthritis

Hydroxychloroquine May Lower Hyperlipidemia Risk in Early Rheumatoid Arthritis

Reduced risk for hyperlipidemia with hydroxychloroquine vs. other disease-modifying antirheumatic drugs.

Fenofibrate May Mimic Cannabinoid Receptor Stimulation

Fenofibrate May Mimic Cannabinoid Receptor Stimulation

By

Researchers have discovered that a common medication indicated for the treatment of high cholesterol may stimulate the same peroxisome proliferator-activated receptors (PPARs) as cannabinoids, which could lead to a new class of cannabis-like drugs to treat a range of conditions.

High Cholesterol in Young Adulthood Heightens CHD Risk

High Cholesterol in Young Adulthood Heightens CHD Risk

By

Young adults with high cholesterol have an increased risk for developing coronary heart disease later in life.

Nurse-Managed Protocols Improved Outpatient Care in Chronic Illnesses

Nurse-Managed Protocols Improved Outpatient Care in Chronic Illnesses

Outcomes positive for nurse-managed protocols in patients with chronic conditions.

Sign Up for Free e-Newsletters



CME Focus